SRRK Scholar Rock Holding Corp

$39.80

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.scholarrock.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1727196
Address
620 MEMORIAL DRIVE, 2ND FLOOR, CAMBRIDGE, MA, US
Valuation
Market Cap
$2.92B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
7.91
Performance
EPS
$-2.47
Dividend Yield
—
Profit Margin
0.00%
ROE
-83.00%
Technicals
50D MA
$33.99
200D MA
$26.59
52W High
$46.98
52W Low
$6.76
Fundamentals
Shares Outstanding
95M
Target Price
$50.50
Beta
0.58

SRRK EPS Estimates vs Actual

● Estimated
● Actual

SRRK News & Sentiment

Sep 26, 2025 • Benzinga SOMEWHAT-BULLISH
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday - Robo.ai ( NASDAQ:AIIO ) , Aquestive Therapeutics ( NASDAQ:AQST )
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. ( NASDAQ: CRNX ) rose sharply during Friday's session after the FDA approved PALSONIFY. Also, Baird and JMP Securities raised their respective price targets on ...
Sep 23, 2025 • Benzinga NEUTRAL
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Scholar Rock Holding ( NASDAQ:SRRK )
The U.S. Food and Drug Administration ( FDA ) on Tuesday issued a Complete Response Letter ( CRL ) for Scholar Rock's SRRK apitegromab Biologics License Application ( BLA ) for spinal muscular atrophy ( SMA ) .
Sep 23, 2025 • Benzinga NEUTRAL
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Diginex ( NASDAQ:DGNX ) , Strive ( NASDAQ:ASST )
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Firefly Aerospace Inc. FLY fell sharply in pre-market trading following second-quarter results. The company posted a second-quarter loss of $5.78 per share, versus a year-ago loss of $4.60 ...
Sep 15, 2025 • Motley Fool BULLISH
Why Scholar Rock Stock Bounced Higher on Monday
One pundit believes the share price could rise in excess of 50%.
Sep 08, 2025 • Benzinga SOMEWHAT-BULLISH
How Do Investors Really Feel About Scholar Rock Holding? - Scholar Rock Holding ( NASDAQ:SRRK )
Scholar Rock Holding's SRRK short percent of float has risen 4.04% since its last report. The company recently reported that it has 15.47 million shares sold short, which is 28.81% of all regular shares that are available for trading.
Sep 01, 2025 • Benzinga SOMEWHAT-BULLISH
Here's How Much $1000 Invested In Scholar Rock Holding 5 Years Ago Would Be Worth Today - Scholar Rock Holding ( NASDAQ:SRRK )
Scholar Rock Holding SRRK has outperformed the market over the past 5 years by 4.21% on an annualized basis producing an average annual return of 17.71%. Currently, Scholar Rock Holding has a market capitalization of $3.16 billion.
Sentiment Snapshot

Average Sentiment Score:

0.260
50 articles with scored sentiment

Overall Sentiment:

Bullish

SRRK Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Mar 17, 2025
Dec 31, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.61
  • Estimate: $-0.63
  • Whisper: —
  • Surprise %: 3.0%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.06 Surprise
  • Reported EPS: $-0.66
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: -10.7%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.60
  • Estimate: $-0.61
  • Whisper: —
  • Surprise %: 1.6%
May 07, 2024
Mar 31, 2024 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.59
  • Estimate: $-0.51
  • Whisper: —
  • Surprise %: -15.7%
Mar 19, 2024
Dec 31, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.50
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: -2.0%
Nov 07, 2023
Sep 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.53
  • Estimate: $-0.52
  • Whisper: —
  • Surprise %: -1.9%
Aug 09, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $-0.47
  • Estimate: $-0.56
  • Whisper: —
  • Surprise %: 16.1%
May 09, 2023
Mar 31, 2023 (Pre market)
0.09 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.58
  • Whisper: —
  • Surprise %: 15.5%

Financials